From left to right: Francois Belin, COO of IVI; Prof. Park Sang-chul, President of the Korea Support Committee for IVI; Dr. DoHyeon Jeong, CEO of Raphas
July 25, 2019 – SEOUL, South Korea. IVI and the Korea Support Committee for IVI (KSC) jointly held a donation ceremony in honor of Raphas, which has renewed commitment to support IVI’s vaccine development and delivery for children in developing countries. The Korean biopharmaceutical company, an IVI donor since 2015, will conduct a ‘Giving Vaccine’ campaign to use a portion of its sales to increase contributions to IVI through KSC.
Raphas is recognized as a biotech innovator and emerging global leader in cosmetics products and drug delivery system using dissolving microstructures. The company aims to apply its innovative technology to the development of vaccines that will allow for needle-free delivery, and is developing a tuberculosis vaccine patch in collaboration with Seoul National University.
“It has been our dream to develop a vaccine that is free of pain and safe from infection caused by contaminated syringes and does not require cold chain supply,” said Dr. DoHyeon Jeong, CEO of Raphas at the ceremony at IVI headquarters. “We will continue our corporate social responsibility activities to help save and improve the lives of children and to enable them to realize their future dreams. As a responsible corporate citizen, we will continue to expand our contributions to the global society.”
Vaccine Patch under development by Raphas